Romanian researchers randomized69 HD patients with anemiato receive, for 12 months, 300 mgintravenous ascorbic acid 3 times aweek, or placebo.
After the first 3 months, theascorbic acid group had a significantlygreater rise in hemoglobincompared with the control group.Doses of erythropoiesis-stimulatingagent decreased significantly after 6months only in the intervention arm,but remained stable in the controlgroup. Serum ferritin increased onlyin patients on ascorbic acid and onlyafter 6 months. Iron requirementsdecreased significantly only in theintervention group.
Enjoying our content?
Thanks for visiting Renal & Urology News. We hope you’re enjoying the latest clinical news, full-length features, case studies, and more.
You’ve viewed {{metering-count}} of {{metering-total}} articles this month. If you wish to read unlimited content, please log in or register below. Registration is free.
{{login-button}} {{register-button}}
Log in to continue reading this article.
Don’t miss out on today’s top content on Renal & Urology News. Register for free and gain unlimited access to:
- Clinical News, with personalized daily picks for you
- Case Studies
- Conference Coverage
- Full-Length Features
- Drug Monographs
- And More
{{login-button}} {{register-button}}
Want to read more?
Please login or register first to view this content.
